Integrated genetic and pharmacologic interrogation of rare cancers

Identifying therapeutic targets in rare cancers remains challenging due to the paucity of established models to perform preclinical studies. As a proof-of-concept, we developed a patient-derived cancer cell line, CLF-PED-015-T, from a paediatric patient with a rare undifferentiated sarcoma. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Andrew L., Tseng, Yuen-Yi, Cowley, Glenn S., Jonas, Oliver, Cheah, Jaime H., Kynnap, Bryan D., Doshi, Mihir B., Oh, Coyin, Meyer, Stephanie C., Church, Alanna J., Gill, Shubhroz, Bielski, Craig M., Keskula, Paula, Imamovic, Alma, Howell, Sara, Kryukov, Gregory V., Clemons, Paul A., Tsherniak, Aviad, Vazquez, Francisca, Crompton, Brian D., Shamji, Alykhan F., Rodriguez-Galindo, Carlos, Janeway, Katherine A., Roberts, Charles W. M., Stegmaier, Kimberly, van Hummelen, Paul, Cima, Michael J., Langer, Robert S., Garraway, Levi A., Schreiber, Stuart L., Root, David E., Hahn, William C., Boehm, Jesse S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917959/
https://www.ncbi.nlm.nih.gov/pubmed/27329820
http://dx.doi.org/10.1038/ncomms11987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917959/
https://www.ncbi.nlm.nih.gov/pubmed/27329820
http://dx.doi.org/10.1038/ncomms11987

Ejemplares similares